Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aranesp Once Monthly in Non-Dialysis CKD Patients
NCT00111098Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2004
- Primary completion
- Nov 2005
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 3, open-label, single-arm trial of darbepoetin alfa in anemia of chronic kidney disease, sponsored by Amgen. Primary endpoint: Proportion of subjects maintained with mean Hb >= 11.0 g/dL at 28 weeks. Started Mar 2004; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT00111098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111098.